Literature DB >> 34295062

Pancreatic Cancer: "Whether to Cross the Border"?

Kailash Chand Kurdia1, Vinay K Kapoor2.   

Abstract

Entities:  

Keywords:  Borderline resectable pancreatic cancer; Neoadjuvant therapy; Pancreatic adenocarcinoma; Pancreatic cancer; Pancreatic ductal adenocarcinoma

Year:  2021        PMID： 34295062      PMCID： PMC8272748          DOI： 10.1007/s13193-021-01341-5

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN： 0975-7651


× No keyword cloud information.
  21 in total

1.  Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.

Authors:  Tsutomu Fujii; Sohei Satoi; Suguru Yamada; Kenta Murotani; Hiroaki Yanagimoto; Hideki Takami; Tomohisa Yamamoto; Mitsuro Kanda; So Yamaki; Satoshi Hirooka; Masanori Kon; Yasuhiro Kodera
Journal:  J Gastroenterol       Date:  2016-05-11       Impact factor: 7.527

2.  Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Naru Kondo; Naoya Nakagawa; Shinya Takahashi; Taijiro Sueda
Journal:  Cancer Chemother Pharmacol       Date:  2016-11-22       Impact factor: 3.333

3.  Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas.

Authors:  V K Mehta; G Fisher; J A Ford; J C Poen; M A Vierra; H Oberhelman; J Niederhuber; J A Bastidas
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

4.  Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets.

Authors:  Riccardo Casadei; Mariacristina Di Marco; Claudio Ricci; Donatella Santini; Carla Serra; Lucia Calculli; Marielda D'Ambra; Alessandra Guido; Antonio Maria Morselli-Labate; Francesco Minni
Journal:  J Gastrointest Surg       Date:  2015-07-30       Impact factor: 3.452

5.  International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.

Authors:  Shuji Isaji; Shugo Mizuno; John A Windsor; Claudio Bassi; Carlos Fernández-Del Castillo; Thilo Hackert; Aoi Hayasaki; Matthew H G Katz; Sun-Whe Kim; Masashi Kishiwada; Hirohisa Kitagawa; Christoph W Michalski; Christopher L Wolfgang
Journal:  Pancreatology       Date:  2017-11-22       Impact factor: 3.996

6.  Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS).

Authors:  Maximilian Bockhorn; Faik G Uzunoglu; Mustapha Adham; Clem Imrie; Miroslav Milicevic; Aken A Sandberg; Horacio J Asbun; Claudio Bassi; Markus Büchler; Richard M Charnley; Kevin Conlon; Laureano Fernandez Cruz; Christos Dervenis; Abe Fingerhutt; Helmut Friess; Dirk J Gouma; Werner Hartwig; Keith D Lillemoe; Marco Montorsi; John P Neoptolemos; Shailesh V Shrikhande; Kyoichi Takaori; William Traverso; Yogesh K Vashist; Charles Vollmer; Charles J Yeo; Jakob R Izbicki
Journal:  Surgery       Date:  2014-02-07       Impact factor: 3.982

7.  Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer.

Authors:  Bikram Shrestha; Yifei Sun; Farzana Faisal; Victoria Kim; Kevin Soares; Alex Blair; Joseph M Herman; Amol Narang; Avani S Dholakia; Lauren Rosati; Amy Hacker-Prietz; Linda Chen; Daniel A Laheru; Ana De Jesus-Acosta; Dung T Le; Ross Donehower; Nilofar Azad; Luis A Diaz; Adrian Murphy; Valerie Lee; Elliot K Fishman; Ralph H Hruban; Tingbo Liang; John L Cameron; Martin Makary; Matthew J Weiss; Nita Ahuja; Jin He; Christopher L Wolfgang; Chiung-Yu Huang; Lei Zheng
Journal:  Cancer Med       Date:  2017-06-21       Impact factor: 4.452

Review 8.  Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies.

Authors:  Han-Xiang Zhan; Jian-Wei Xu; Dong Wu; Zhi-Yang Wu; Lei Wang; San-Yuan Hu; Guang-Yong Zhang
Journal:  Cancer Med       Date:  2017-05-23       Impact factor: 4.452

9.  Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.

Authors:  Qiancheng Hu; Dan Wang; Ye Chen; Xiaofen Li; Peng Cao; Dan Cao
Journal:  Radiat Oncol       Date:  2019-07-10       Impact factor: 3.481

10.  Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis.

Authors:  Long Pan; Jing Fang; Chenhao Tong; Mingyu Chen; Bin Zhang; Sarun Juengpanich; Yifan Wang; Xiujun Cai
Journal:  World J Surg Oncol       Date:  2019-12-31       Impact factor: 2.754
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.